LX2006

LX2006 is an investigational adeno-associated virus (AAV)-based gene therapy developed for the treatment of Friedreich's ataxia cardiomyopathy (FA cardiomyopathy). It is designed to deliver a functional copy of the FXN gene, which encodes the frataxin protein, directly to myocardial (heart) cells via intravenous infusion. By increasing frataxin levels in cardiac mitochondria, LX2006 aims to restore mitochondrial function and energy production in heart muscle cells. Preclinical studies have shown that LX2006 can reverse cardiac abnormalities associated with FA and improve both cardiac function and survival. The therapy is currently being evaluated in a phase 1/2 clinical trial (SUNRISE-FA) for safety and efficacy in patients with FA cardiomyopathy. The FDA has granted Fast Track, Rare Pediatric Disease, and Orphan Drug designations to LX2006 for this indication[1][2][3][4][5][8].

Other names

AAVrh.10hFXN